Evidence map›Paper›PMID 35336896›Full record

ArticleViruses2022

The Analogs of Furanyl Methylidene Rhodanine Exhibit Broad-Spectrum Inhibitory and Inactivating Activities against Enveloped Viruses, including SARS-CoV-2 and Its Variants.

Jing Pu, Xiaoyang He, Wei Xu, Cong Wang, Qiaoshuai Lan, Chen Hua, Kai Wang, Lu Lu, Shibo Jiang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. A hepcidin homolog fromVirulence · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Comparison of Cell Fusions Induced by Influenza Virus and SARS-CoV-2.International journal of molecular sciences · 2022
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Jing PuKey Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Institute of Infectious Disease and Biosecurity, Biosafety Level 3 Laboratory, Shanghai Medical College, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, Fudan University, Shanghai 200438, China.
Xiaoyang HeBeijing Institute of Radiation Medicine, Beijing 200032, China.ORCID 0000-0003-0958-5108
Wei XuKey Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Institute of Infectious Disease and Biosecurity, Biosafety Level 3 Laboratory, Shanghai Medical College, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, Fudan University, Shanghai 200438, China.
Cong WangKey Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Institute of Infectious Disease and Biosecurity, Biosafety Level 3 Laboratory, Shanghai Medical College, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, Fudan University, Shanghai 200438, China.
Qiaoshuai LanKey Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Institute of Infectious Disease and Biosecurity, Biosafety Level 3 Laboratory, Shanghai Medical College, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, Fudan University, Shanghai 200438, China.ORCID 0000-0001-5524-3542
Chen HuaKey Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Institute of Infectious Disease and Biosecurity, Biosafety Level 3 Laboratory, Shanghai Medical College, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, Fudan University, Shanghai 200438, China.
Kai WangKey Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Institute of Infectious Disease and Biosecurity, Biosafety Level 3 Laboratory, Shanghai Medical College, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, Fudan University, Shanghai 200438, China.
Lu LuKey Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Institute of Infectious Disease and Biosecurity, Biosafety Level 3 Laboratory, Shanghai Medical College, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, Fudan University, Shanghai 200438, China.ORCID 0000-0002-2255-0391
Shibo JiangKey Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Institute of Infectious Disease and Biosecurity, Biosafety Level 3 Laboratory, Shanghai Medical College, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, Fudan University, Shanghai 200438, China.ORCID 0000-0001-8283-7135
Shanghai Medical College of Fudan University · CNBeijing Radiation Center · CN

Funding

Program of Shanghai Academic/Technology Research Leader 20XD1420300 to L.L.the National Key Research and Development Program of China 2021YFC2300703 to L.L.the National Natural Science Foundation of China 82161138002 and 92169112 to S.J.; 82002142 to S.X.
6 · The paper itself

Abstract

In recent years, infectious diseases caused by viral infections have seriously endangered human health, especially COVID-19, caused by SARS-CoV-2, which continues to spread worldwide. The development of broad-spectrum antiviral inhibitors is urgently needed. Here, we report a series of small-molecule compounds that proved effective against human coronaviruses (HCoV), such as SARS-CoV-2 and its variants of concern (VOCs), including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529), SARS-CoV, MERS-CoV, HCoV-OC43, and other viruses with class I viral fusion proteins, such as influenza virus, Ebola virus (EBOV), Nipah virus (NiV), and Lassa fever virus (LASV). They are also effective against class II enveloped viruses represented by ZIKV and class III enveloped viruses represented by vesicular stomatitis virus (VSV). Further studies have shown that these compounds may exert antiviral effects through a variety of mechanisms, including inhibiting the formation of the six-helix bundle, which is a typical feature of enveloped virus fusion with cell membranes, and/or targeting viral membrane to inactivate cell-free virions. These compounds are expected to become drug candidates against SARS-CoV-2 and other enveloped viruses.

Indexed as

COVID-19 Drug TreatmentRhodanineZika VirusZika Virus InfectionHumansSARS-CoV-2Rhodanineenveloped virusinactivatorinhibitorSARS-CoV-2small-molecule compound

Identifiers

PMID35336896
PMCPMC8954792
OpenAlexW4214728391

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.